Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap

Soligenix, Inc. (NASDAQ:SNGX) – Equities researchers at Zacks Small Cap issued their Q1 2025 earnings estimates for Soligenix in a research note issued to investors on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz anticipates that the biopharmaceutical company will earn ($0.67) per share for the quarter. The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.79) EPS and FY2027 earnings at ($1.75) EPS.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. During the same quarter in the previous year, the business posted ($12.66) earnings per share.

Soligenix Stock Down 2.6 %

Soligenix stock opened at $2.21 on Thursday. The business’s 50-day simple moving average is $2.34 and its 200 day simple moving average is $3.07. The stock has a market cap of $5.55 million, a price-to-earnings ratio of -0.29 and a beta of 2.03. Soligenix has a 12-month low of $1.83 and a 12-month high of $14.92.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Soligenix stock. Geode Capital Management LLC boosted its holdings in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,094 shares of the biopharmaceutical company’s stock after buying an additional 7,729 shares during the period. Geode Capital Management LLC owned approximately 1.04% of Soligenix worth $71,000 as of its most recent SEC filing. Institutional investors own 3.60% of the company’s stock.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.